2026 Global: Anti-Tuberculosis Drug Market -Competitive Review (2032) report
Description
The 2026 Global: Anti-Tuberculosis Drug Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for anti-tuberculosis drug market by geography and historical trend. The scope of the report extends to sizing of the anti-tuberculosis drug market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Johnson & Johnson (Janssen), Otsuka Pharmaceutical, Pfizer, Sanofi, GlaxoSmithKline (GSK), Lupin, Cipla, Macleods, Viatris (including legacy Mylan/Upjohn), and Novartis/Sandoz are widely recognized among the ten major companies active in the anti‑tuberculosis drug market based on market reports and industry listings. Johnson & Johnson’s Janssen unit leads in drug‑resistant TB with bedaquiline and has secured major regulatory approvals and global programmatic uptake that position it as a market leader. Otsuka is notable for delamanid and its R&D focus on multidrug‑resistant TB regimens, contributing meaningfully to second‑line therapy options. Pfizer and Sanofi appear frequently in market analyses as large multinational suppliers of both first‑line and second‑line TB medicines and partners in global procurement channels.
Large generic and specialty manufacturers—Lupin, Cipla, Macleods, and Viatris—dominate supply of first‑line agents and institutional procurement for high‑burden countries, supplying rifampin, isoniazid and fixed‑dose combinations through Global Fund and national programs. Lupin specifically markets itself as the largest supplier of first‑line anti‑TB drugs globally and holds strong market share in rifampin and institutional tenders, leveraging API and fermentation capabilities to supply low‑cost generics. Cipla and Macleods are repeatedly listed in procurement catalogs and market reports as major producers of first‑line fixed‑dose combinations and pediatric formulations used in national TB programs. Viatris (Mylan/Upjohn legacy) and Sandoz/Novartis serve broad generic portfolios and supply channels that ensure availability across low‑ and middle‑income markets, often participating in WHO‑prequalification and large tenders.
These ten companies collectively shape market dynamics through a mix of patented novel agents, generics production, and participation in global procurement and access initiatives reported by industry analysts and market research firms. Innovators such as J&J and Otsuka drive second‑line and drug‑resistant TB therapeutic advances, while generics manufacturers—Lupin, Cipla, Macleods, Viatris and Sandoz—ensure scale, affordability and geographic reach for first‑line regimens, often supplying Global Fund and national programs. Market reports project continued growth driven by persistent TB burden, expansion of oral therapies, and uptake of newer agents for MDR/XDR TB, with the combined activities of these companies central to treatment access and evolving regimen adoption worldwide.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for anti-tuberculosis drug market by geography and historical trend. The scope of the report extends to sizing of the anti-tuberculosis drug market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Johnson & Johnson (Janssen), Otsuka Pharmaceutical, Pfizer, Sanofi, GlaxoSmithKline (GSK), Lupin, Cipla, Macleods, Viatris (including legacy Mylan/Upjohn), and Novartis/Sandoz are widely recognized among the ten major companies active in the anti‑tuberculosis drug market based on market reports and industry listings. Johnson & Johnson’s Janssen unit leads in drug‑resistant TB with bedaquiline and has secured major regulatory approvals and global programmatic uptake that position it as a market leader. Otsuka is notable for delamanid and its R&D focus on multidrug‑resistant TB regimens, contributing meaningfully to second‑line therapy options. Pfizer and Sanofi appear frequently in market analyses as large multinational suppliers of both first‑line and second‑line TB medicines and partners in global procurement channels.
Large generic and specialty manufacturers—Lupin, Cipla, Macleods, and Viatris—dominate supply of first‑line agents and institutional procurement for high‑burden countries, supplying rifampin, isoniazid and fixed‑dose combinations through Global Fund and national programs. Lupin specifically markets itself as the largest supplier of first‑line anti‑TB drugs globally and holds strong market share in rifampin and institutional tenders, leveraging API and fermentation capabilities to supply low‑cost generics. Cipla and Macleods are repeatedly listed in procurement catalogs and market reports as major producers of first‑line fixed‑dose combinations and pediatric formulations used in national TB programs. Viatris (Mylan/Upjohn legacy) and Sandoz/Novartis serve broad generic portfolios and supply channels that ensure availability across low‑ and middle‑income markets, often participating in WHO‑prequalification and large tenders.
These ten companies collectively shape market dynamics through a mix of patented novel agents, generics production, and participation in global procurement and access initiatives reported by industry analysts and market research firms. Innovators such as J&J and Otsuka drive second‑line and drug‑resistant TB therapeutic advances, while generics manufacturers—Lupin, Cipla, Macleods, Viatris and Sandoz—ensure scale, affordability and geographic reach for first‑line regimens, often supplying Global Fund and national programs. Market reports project continued growth driven by persistent TB burden, expansion of oral therapies, and uptake of newer agents for MDR/XDR TB, with the combined activities of these companies central to treatment access and evolving regimen adoption worldwide.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
